Transcarent to Acquire Accolade in $621M Cash Deal

Dow Jones

08 Jan

By Denny Jacob

Transcarent agreed to acquire healthcare company Accolade for $7.03 a share in cash, bringing the equity value of the deal to around $621 million.

San Francisco-based Transcarent, which provides technology-enabled health and benefit solutions, on Wednesday said its offerings, including those for cancer, surgery and pharmacy benefits, will combine with Accolade's personalized healthcare platform and expertise in areas including primary care.

The offer of $7.03 a share represents a premium of about 110% over Accolade's Tuesday closing stock price of $3.35. Transcarent said it will finance the deal through a fully committed equity financing led by General Catalyst and Glen Tullman's 62 Ventures.

Shares of Seattle-based Accolade more than doubled to $6.88 in recent premarket trading. They were briefly halted at 8:25 a.m. ET ahead of the news.

The deal, expected to close in the second calendar quarter of 2025, has been unanimously approved by both companies' boards.

"We will create a more personalized healthcare experience for people while improving outcomes and driving down costs," said Accolade Chief Executive Rajeev Singh.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

January 08, 2025 09:14 ET (14:14 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2501778632"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2501778632\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2501778632?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-08 22:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501778632","market":"fut","top_or_hot":-1,"title":"Transcarent to Acquire Accolade in $621M Cash Deal","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Transcarent agreed to acquire healthcare company Accolade for $7.03 a share in cash, bringing the equity value of the deal to around $621 million. \n</p>\n<p>\n  San Francisco-based Transcarent, which provides technology-enabled health and benefit solutions, on Wednesday said its offerings, including those for cancer, surgery and pharmacy benefits, will combine with Accolade's personalized healthcare platform and expertise in areas including primary care. \n</p>\n<p>\n  The offer of $7.03 a share represents a premium of about 110% over Accolade's Tuesday closing stock price of $3.35. Transcarent said it will finance the deal through a fully committed equity  financing led by General Catalyst and Glen Tullman's 62 Ventures. \n</p>\n<p>\n  Shares of Seattle-based Accolade more than doubled to $6.88 in recent premarket trading. They were briefly halted at 8:25 a.m. ET ahead of the news. \n</p>\n<p>\n  The deal, expected to close in the second calendar quarter of 2025, has been unanimously approved by both companies' boards. \n</p>\n<p>\n  \"We will create a more personalized healthcare experience for people while improving outcomes and driving down costs,\" said Accolade Chief Executive Rajeev Singh. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2025 09:14 ET (14:14 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Transcarent to Acquire Accolade in $621M Cash Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTranscarent to Acquire Accolade in $621M Cash Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-08 22:14</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Transcarent agreed to acquire healthcare company Accolade for $7.03 a share in cash, bringing the equity value of the deal to around $621 million. \n</p>\n<p>\n  San Francisco-based Transcarent, which provides technology-enabled health and benefit solutions, on Wednesday said its offerings, including those for cancer, surgery and pharmacy benefits, will combine with Accolade's personalized healthcare platform and expertise in areas including primary care. \n</p>\n<p>\n  The offer of $7.03 a share represents a premium of about 110% over Accolade's Tuesday closing stock price of $3.35. Transcarent said it will finance the deal through a fully committed equity  financing led by General Catalyst and Glen Tullman's 62 Ventures. \n</p>\n<p>\n  Shares of Seattle-based Accolade more than doubled to $6.88 in recent premarket trading. They were briefly halted at 8:25 a.m. ET ahead of the news. \n</p>\n<p>\n  The deal, expected to close in the second calendar quarter of 2025, has been unanimously approved by both companies' boards. \n</p>\n<p>\n  \"We will create a more personalized healthcare experience for people while improving outcomes and driving down costs,\" said Accolade Chief Executive Rajeev Singh. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2025 09:14 ET (14:14 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2501778632","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501778632","pubTimestamp":1736345640,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Transcarent agreed to acquire healthcare company Accolade for $7.03 a share in cash, bringing the equity value of the deal to around $621 million.San Francisco-based Transcarent, which provides technology-enabled health and benefit solutions, on Wednesday said its offerings, including those for cancer, surgery and pharmacy benefits, will combine with Accolade's personalized healthcare platform and expertise in areas including primary care.The offer of $7.03 a share represents a premium of about 110% over Accolade's Tuesday closing stock price of $3.35. Transcarent said it will finance the deal through a fully committed equity  financing led by General Catalyst and Glen Tullman's 62 Ventures.Shares of Seattle-based Accolade more than doubled to $6.88 in recent premarket trading. They were briefly halted at 8:25 a.m. ET ahead of the news.The deal, expected to close in the second calendar quarter of 2025, has been unanimously approved by both companies' boards.\"We will create a more perso","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","ACCD":"Accolade, Inc."},"translate_title":"Transcarent将以6.21亿美元现金收购Accolade","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACCD":1},"content_text":"By Denny Jacob \n\n\n \n\n\n  Transcarent agreed to acquire healthcare company Accolade for $7.03 a share in cash, bringing the equity value of the deal to around $621 million. \n\n\n  San Francisco-based Transcarent, which provides technology-enabled health and benefit solutions, on Wednesday said its offerings, including those for cancer, surgery and pharmacy benefits, will combine with Accolade's personalized healthcare platform and expertise in areas including primary care. \n\n\n  The offer of $7.03 a share represents a premium of about 110% over Accolade's Tuesday closing stock price of $3.35. Transcarent said it will finance the deal through a fully committed equity  financing led by General Catalyst and Glen Tullman's 62 Ventures. \n\n\n  Shares of Seattle-based Accolade more than doubled to $6.88 in recent premarket trading. They were briefly halted at 8:25 a.m. ET ahead of the news. \n\n\n  The deal, expected to close in the second calendar quarter of 2025, has been unanimously approved by both companies' boards. \n\n\n  \"We will create a more personalized healthcare experience for people while improving outcomes and driving down costs,\" said Accolade Chief Executive Rajeev Singh. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2025 09:14 ET (14:14 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"merge","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}